<VariationArchive VariationID="1073797" VariationName="NM_000020.3(ACVRL1):c.412_413del (p.Leu138fs)" VariationType="Deletion" Accession="VCV001073797" Version="12" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-06-23" DateCreated="2021-05-10" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1062672" VariationID="1073797">
      <GeneList>
        <Gene Symbol="ACVRL1" FullName="activin A receptor like type 1" GeneID="94" HGNC_ID="HGNC:175" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q13.13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="51906944" stop="51923361" display_start="51906944" display_stop="51923361" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="52301201" stop="52317144" display_start="52301201" display_stop="52317144" Strand="+" />
          </Location>
          <OMIM>601284</OMIM>
          <Haploinsufficiency last_evaluated="2016-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ACVRL1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2016-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ACVRL1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000020.3(ACVRL1):c.412_413del (p.Leu138fs)</Name>
      <CanonicalSPDI>NC_000012.12:51913656:CT:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>12q13.13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="51913657" stop="51913658" display_start="51913657" display_stop="51913658" variantLength="2" positionVCF="51913656" referenceAlleleVCF="CCT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="52307441" stop="52307442" display_start="52307441" display_stop="52307442" variantLength="2" positionVCF="52307440" referenceAlleleVCF="CCT" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>L138fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.52307441_52307442del" Assembly="GRCh37">
            <Expression>NC_000012.11:g.52307441_52307442del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.51913657_51913658del" Assembly="GRCh38">
            <Expression>NC_000012.12:g.51913657_51913658del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009549.1" sequenceAccession="NG_009549" sequenceVersion="1" change="g.11240_11241del">
            <Expression>NG_009549.1:g.11240_11241del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000020.3" sequenceAccession="NM_000020" sequenceVersion="3" change="c.412_413del" MANESelect="true">
            <Expression>NM_000020.3:c.412_413del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000011.2" sequenceAccession="NP_000011" sequenceVersion="2" change="p.Leu138fs">
            <Expression>NP_000011.2:p.Leu138fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077401.2" sequenceAccession="NM_001077401" sequenceVersion="2" change="c.412_413del">
            <Expression>NM_001077401.2:c.412_413del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001070869.1" sequenceAccession="NP_001070869" sequenceVersion="1" change="p.Leu138fs">
            <Expression>NP_001070869.1:p.Leu138fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_543" sequenceAccession="LRG_543">
            <Expression>LRG_543:g.11240_11241del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_543t1" sequenceAccession="LRG_543t1">
            <Expression>LRG_543t1:c.412_413del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2139067412" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000020.3(ACVRL1):c.412_413del (p.Leu138fs) AND Telangiectasia, hereditary hemorrhagic, type 2" Accession="RCV001386902" Version="12">
        <ClassifiedConditionList TraitSetID="2259">
          <ClassifiedCondition DB="MedGen" ID="C1838163">Telangiectasia, hereditary hemorrhagic, type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-05-06" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000020.3(ACVRL1):c.412_413del (p.Leu138fs) AND Cardiovascular phenotype" Accession="RCV002322366" Version="2">
        <ClassifiedConditionList TraitSetID="32616">
          <ClassifiedCondition DB="MedGen" ID="CN230736">Cardiovascular phenotype</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-03-07" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-05-06" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2021-05-10" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15879500</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="32616" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="33389" Type="Finding">
              <Name>
                <ElementValue Type="Preferred">Cardiovascular phenotype</ElementValue>
              </Name>
              <XRef ID="CN230736" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2259" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3671" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Telangiectasia, hereditary hemorrhagic, type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Telangiectasia, hereditary hemorrhagic, type 2</ElementValue>
                <XRef ID="MONDO:0010880" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Osler Weber Rendu syndrome type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HHT2</ElementValue>
                <XRef Type="MIM" ID="600376" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ORW2</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000528884" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512240" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528531" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515719" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000241591" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500010" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515716" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509788" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000511258" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. The most common clinical manifestation is spontaneous and recurrent nosebleeds (epistaxis) beginning on average at age 12 years. Telangiectases (small AVMs) are characteristically found on the lips, tongue, buccal and gastrointestinal (GI) mucosa, face, and fingers. The appearance of telangiectases is generally later than epistaxis but may be during childhood. Large AVMs occur most often in the lungs, liver, or brain; complications from bleeding or shunting may be sudden and catastrophic. A minority of individuals with HHT have GI bleeding, which is rarely seen before age 50 years.</Attribute>
                <XRef ID="NBK1351" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9901" />
                <XRef ID="9901" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301525</ID>
                <ID Source="BookShelf">NBK1351</ID>
              </Citation>
              <Citation Type="general" Abbrev="HHT Foundation Int'l, 2011">
                <ID Source="PubMed">19553198</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Shovlin et al., 2000">
                <ID Source="PubMed">10751092</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="HHT Foundation Int'l, 2020">
                <ID Source="PubMed">32894695</ID>
              </Citation>
              <XRef ID="774" DB="Orphanet" />
              <XRef ID="C1838163" DB="MedGen" />
              <XRef ID="MONDO:0010880" DB="MONDO" />
              <XRef Type="MIM" ID="600376" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3112959" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="8879757|MedGen:C1838163" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001587301" DateUpdated="2024-02-20" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15879500</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Leu138Glyfs*30) in the ACVRL1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ACVRL1 are known to be pathogenic (PMID: 15879500). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with ACVRL1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1073797). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ACVRL1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000012.11:g.52307441_52307442del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1838163" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4015631" SubmissionDate="2022-01-04" DateLastUpdated="2022-01-08" DateCreated="2022-01-08">
        <ClinVarSubmissionID localKey="3215465|OMIM:600376" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002049516" DateUpdated="2022-01-08" DateCreated="2022-01-08" Type="SCV" Version="1" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" OrgAbbreviation="ARUP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-09-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The ACVRL1 c.412_413delCT; p.Leu138GlyfsTer30 variant, to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: 1073797). This variant is absent from the Genome Aggregation Database, indicating it is not a common polymorphism. This variant causes a frameshift by deleting 2 nucleotides, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Additionally, several downstream truncating variants have been described in individuals with hereditary hemorrhagic telangiectasia (HHT) and are considered pathogenic (Abdalla 2003, McDonald 2011, Komiyama 2014, McDonald 2020). Based on available information, this variant is considered to be pathogenic. References: Abdalla SA et al. Disease-associated mutations in conserved residues of ALK-1 kinase domain. Eur J Hum Genet. 2003 Apr;11(4):279-87. PMID: 12700602. Komiyama M et al. Hereditary hemorrhagic telangiectasia in Japanese patients. J Hum Genet. 2014 Jan;59(1):37-41. PMID: 24196379. McDonald J et al. Molecular diagnosis in hereditary hemorrhagic telangiectasia: findings in a series tested simultaneously by sequencing and deletion/duplication analysis. Clin Genet. 2011 Apr;79(4):335-44. PMID: 21158752. McDonald J et al. Curaçao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2). Genet Med. 2020 Jul;22(7):1201-1205. PMID: 32300199.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/ythvkvge/arup_molecular_germline_variant_investigation_process_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000012.11:g.52307441_52307442delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="600376" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>ARUP Molecular 2021</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5113270" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2022-11-29">
        <ClinVarSubmissionID localKey="a76255|MedGen:CN230736" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002627149" DateUpdated="2024-05-01" DateCreated="2022-11-29" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-03-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The c.412_413delCT pathogenic mutation, located in coding exon 3 of the ACVRL1 gene, results from a deletion of two nucleotides at nucleotide positions 412 to 413, causing a translational frameshift with a predicted alternate stop codon (p.L138Gfs*30). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. This nucleotide position is not well conserved in available vertebrate species.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ACVRL1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000020.2:c.412_413delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Finding">
          <Trait Type="Finding">
            <XRef DB="MedGen" ID="CN230736" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5113270" TraitType="Finding" MappingType="XRef" MappingValue="CN230736" MappingRef="MedGen">
        <MedGen CUI="CN230736" Name="Cardiovascular phenotype" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4015631" TraitType="Disease" MappingType="XRef" MappingValue="600376" MappingRef="OMIM">
        <MedGen CUI="C1838163" Name="Telangiectasia, hereditary hemorrhagic, type 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3112959" TraitType="Disease" MappingType="XRef" MappingValue="C1838163" MappingRef="MedGen">
        <MedGen CUI="C1838163" Name="Telangiectasia, hereditary hemorrhagic, type 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

